10-Q: Butterfly Network Reports Q2 2024 Results, Revenue Growth Driven by iQ3 Launch

Butterfly Network's Q2 2024 results show a 16.2% increase in total revenue year-over-year, driven by strong product sales, particularly the new iQ3 device, and growth in software and services.

Summary

• Butterfly Network reported a total revenue of $21.487 million for the three months ended June 30, 2024, a 16.2% increase compared to $18.487 million in the same period of 2023.
• Product revenue increased by 19.4% to $14.648 million, driven by the launch of the iQ3 device and international sales growth, while software and other services revenue grew by 10.1% to $6.839 million.
• The company's net loss for the quarter was $15.706 million, compared to a net loss of $28.671 million in Q2 2023.
• Operating expenses decreased significantly, with research and development down by 39.8% and general and administrative expenses down by 31.3% due to cost-cutting measures.
• For the six months ended June 30, 2024, total revenue was $39.143 million, a 15.3% increase from $33.963 million in the same period of 2023, with a net loss of $37.467 million compared to $62.211 million in the prior year.
• The company expects its current cash and cash equivalents of $102.1 million to fund operations for at least the next twelve months.
• Butterfly Network is exploring non-dilutive capital options like grants and debt before potentially considering equity financing to reach profitability.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and cost reduction, with a clear plan for future financing. However, the company is still operating at a loss and faces significant risks, which tempers the overall sentiment.

Positives

• Revenue growth was strong, driven by both product sales and software services.
• The company significantly reduced its net loss compared to the same period last year.
• Operating expenses were substantially reduced, particularly in research and development and general and administrative areas.
• International sales volume more than doubled, indicating successful expansion efforts.
• The company has a clear plan to extend its cash runway and is exploring non-dilutive financing options.
• The launch of the iQ3 device is contributing to increased product revenue.
• A new partnership is expected to yield significant cost savings.

Negatives

• The company continues to incur net losses and negative cash flows from operating activities.
• Software and other services mix decreased slightly due to a larger increase in product revenue.
• The company is still reliant on external financing to reach profitability.
• Two large medical school deployments in the prior year did not repeat in 2024, impacting U.S. sales volume.
• The company has significant contractual obligations for leases, technology licenses, and inventory supply agreements.

Risks

• The company's growth depends on its ability to attract and retain customers.
• Failure to manage growth effectively could harm the business.
• The company's projections are subject to risks, assumptions, estimates, and uncertainties.
• The business is subject to a variety of U.S. and foreign laws, which are subject to change.
• The pricing of products and services and reimbursement for medical procedures could impact revenue.
• Failure to protect or enforce intellectual property rights could harm the business.
• Economic downturns and political and market conditions could adversely affect the business.
• The company is involved in ongoing litigation, which could result in significant costs and liabilities.

Future Outlook

The company expects its current cash and cash equivalents to fund operations for at least the next twelve months and is exploring non-dilutive capital options before potentially considering equity financing to reach profitability. They anticipate annual cost savings of approximately $10 million from a new partnership.

Management Comments

• Management believes the company's cash and cash equivalents will be sufficient to fund operations for at least the next twelve months.
• The company expects to raise capital before 2027 to reach profitability, first seeking non-dilutive capital.
• Management is focused on growing revenue and investing in the business.
• The company has taken significant actions to reduce its cost of operations and extend its cash runway.

Industry Context

The company operates in the competitive medical imaging market, facing competition from companies with greater financial and marketing resources. The focus on portable, affordable ultrasound technology aligns with the trend towards point-of-care diagnostics and remote patient management. The company's growth in software and services is also in line with the industry's shift towards recurring revenue models.

Comparison to Industry Standards

• Butterfly Network's revenue growth of 16.2% in Q2 2024 is a positive sign, but it is important to compare this to the growth rates of other medical device companies in the ultrasound space, such as Philips, GE Healthcare, and Siemens Healthineers, which typically have more established market positions and broader product portfolios.
• The company's focus on handheld, point-of-care ultrasound devices differentiates it from traditional players, but it also means that its market penetration and adoption rates may differ significantly from those of larger companies.
• The reduction in operating expenses, particularly in R&D, is a positive step towards profitability, but it is crucial to assess whether these cost-cutting measures will impact the company's ability to innovate and compete effectively in the long term.
• The company's software and services mix, while growing, is still a smaller portion of its total revenue compared to some other digital health companies, indicating a potential area for future growth and margin expansion.
• The company's cash burn rate and runway are critical metrics to monitor, especially in comparison to other companies in the medical device and digital health sectors, as it indicates the company's ability to sustain operations and fund growth initiatives.

Corporate Governance

Legal Proceedings

• The company is involved in ongoing litigation, including a putative class action lawsuit and two stockholder derivative actions.
• The company intends to vigorously defend against these actions.
• The company is unable to predict the outcome or reasonably estimate a range of possible loss at this time.

Stakeholder Impact

• Shareholders may be impacted by the company's ongoing losses and potential future capital raises.
• Employees may be impacted by the company's cost-cutting measures and the new partnership with a third-party global technology and business transformation partner.
• Customers may benefit from the company's new products and services, such as the iQ3 device.
• Suppliers may be impacted by the company's inventory purchase commitments.
• Creditors may be impacted by the company's debt obligations.

Next Steps

• The company will continue to invest in its business to grow revenue.
• The company will explore non-dilutive capital options such as grants and debt.
• The company will potentially raise capital through the sale of equity securities.
• The company will implement a new partnership to optimize and lower the cost of certain technical functions.

Key Dates

Keywords

ultrasound, medical devices, digital health, software as a service, SaaS, healthcare, imaging, Butterfly Network, iQ3, financial results